Abstract B199: Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-b199
Abstract: Purpose: Mechanistic findings in preclinical studies demonstrate that antibody blockade of Semaphorin 4D (SEMA4D, CD100) reduces expansion of MDSC and shifts the balance of immune cells within the TME to facilitate tumor rejection. Efficacy is… read more here.
Keywords: combination; targeting tumor; microenvironment first; first class ... See more keywords